Sie suchten nach: cushing (Englisch - Maltesisch)

cushing’s disease
marda ta’ cushing

use in cushing’s disease
użu fil-marda ta’ cushing

common: cushing’s syndrome;
komuni: sindrome ta’ cushing;

hypogonadism male, cushing syndrome, hypothyroidism
kull pakkett fih flixkun wieħed (60 pillola).

systemic corticosteroid effects including cushing's
b’osservazzjoni mill-qrib tal-effetti

rounded (moon shaped) face (cushing’s syndrome)
wiċċ ittundjat (għamla ta’ qamar) (sindrome ta’ cushing)

cases of cushing’s syndrome and adrenal suppression have been reported.
Ġew irrappurtati każijiet tas-sindrome ta’ cushing u soppressjoni adrenali.

cushing's syndrome*, hyperthyroidism*, inappropriate antidiuretic hormone secretion
sindrome ta’ cushing*, ipertirojdiżmu*, tnixxija mhux adattata tal-ormon antidijuretiku

table 1 adverse reactions in the phase iii study in cushing’s disease patients
tabella 1 reazzjonijiet mhux mixtieqa fit-iii fażi tal-istudju f’pazjenti morda bil-marda ta’ cushing

the maximal dose that was used for treatment of cushing’s syndrome is 1600 mg/day.
id-doża massima li ntużat għall-kura tas- sindrome ta’ cushing hija 1600 mg/jum.

a total of 201 cushing’s disease patients received signifor in phase ii and iii studies.
total ta' 201 pazjent morda bil-marda ta’ cushing ingħataw signifor waqt it-ii u t-iii fażijiet tal-istudji.

age has been found to be a covariate in the population pharmacokinetic analysis of cushing’s disease patients.
instab li l-età kienet kovarjant fl-analiżi farmakokinetika tal-popolazzjoni f'pazjenti morda bil-marda ta’ cushing.

body weight has been found to be a covariate in the population pharmacokinetic analysis of cushing’s disease patients.
instab li l-piż tal-ġisem kien kovarjant fl-analiżi farmakokinetika tal-popolazzjoni ta’ pazjenti morda bil-marda ta’ cushing.

ketoconazole hra is indicated for the treatment of endogenous cushing’s syndrome in adults and adolescents above the age of 12 years.
ketoconazole hra huwa indikat għall-kura tas-sindrome endoġenu ta’ cushing f’persuni adulti u adolexxenti minn 12-il sena ’l fuq.

data from 535 patients with cushing’s disease treated with ketoconazole, along with 13 individual case reports are available in the literature.
fil-letteratura hija disponibbli dejta minn 535 pazjent bil-marda ta’ cushing li ngħataw kura b’ketoconazole, flimkien ma’ 13-il rapport ta’ każijiet individwali.

in addition, mitotane induces a state of adrenal insufficiency which leads to the disappearance of cushing syndrome in patients with secreting adrenal carcinoma and necessitates substitution hormonotherapy.
mitotane jikkawża wkoll stat ta’ insuffiċjenza adrenali li twassal biex ma jidhirx aktar is-sindromu cushing f’pazjenti b’karċinoma adrenali li tnixxi u li tirrikjedi terapija ta’ sostituzzjoni bl-ormoni.

antacids (e.g. ranitidine, cimetidine) aminoglutethimide – a medicine used to treat cushing’s syndrome
antaċidi (eż. ranitidine, cimetidine) aminoglutethimide –mediċina użata għall-kura tas-sindromu ta’ cushing

in the absence of specific information, the use in animal suffering from cushing’s syndrome shall be based on the risk-benefit assessment.
fl-assenza ta’ informazzjoni speċifika, l-użu fl-annimali li jbatu mis-sindrome cushing għandu jkun ibbażat fuq il-valutazzjoni ta’ riskju-benefiċċju.

cushing’s disease and acromegaly are both caused by tumours of the pituitary gland (a gland located at the base of the brain).
il-marda ta’ cushing u akromegalija, it-tnejn jiġu kkawżati minn tumuri fil-glandola pitwitarja (glandola li tinsab fil-qiegħ tal-moħħ).

pruban should not be used in dogs with extensive, infected or ulcerated skin lesions or in animals suffering from cushing’ s syndrome (hyperadrenocorticism).
pruban ma għandux jintuża fi klieb b' leżjonijiet tal- ġilda estiżi, infettati jew b' ulċeri jew f' annimali li jbatu mis- sindromu ta 'cushing (iperadrenokortiċiżmu).